Articles

Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study

Department of Haematology, St. Vincent’s Hospital Melbourne, Melbourne, Australia; Faculty of Medicine, University of Melbourne, St. Vincent’s Hospital Melbourne, Melbourne
Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne
Department of Haematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, South Korea; Chonnam National University Medical School, Hwasun, South Korea
Department of Haematology, The Royal Hobart Hospital, Hobart
Department of Haematology, Gachon University Gil Medical Centre, South Korea
Department of Haematology, Concord Repatriation General Hospital, Concord
Department of Haematology, Concord Repatriation General Hospital, Concord, Australia; Faculty of Medicine and Health, University of Sydney, Sydney
Department of Haematology, Royal Adelaide Hospital, Adelaide
School of Medicine, Samsung Medical Centre, South Korea
Border Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre, Albury
Haematology Cancer Care, Sir Charles Gairdner Hospital, Perth
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
Department of Medicine, National Taiwan University, Taipei, Taiwan
Department of Haematology, Middlemore Hospital, Auckland, New Zealand
Department of Haematology, Royal Darwin Hospital, Darwin
Australian Leukaemia and Lymphoma Group, Melbourne
Biostatistics and Medical Writing, WriteSource Medical Pty Ltd, Sydney, Australia; School of Biomedical Sciences, University of New South Wales, Sydney
Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia; School of Medicine, University of Queensland Brisbane
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Centre, Los Angeles, US
Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
Department of Haematology, St. Vincent’s Hospital Melbourne, Melbourne, Australia; Faculty of Medicine, University of Melbourne, St. Vincent’s Hospital Melbourne, Melbourne
Vol. 109 No. 7 (2024): July, 2024 https://doi.org/10.3324/haematol.2023.284238